Hipertensión arterial mineralocorticoidea

Jackson, 2002, New genetic insights in familial hyperaldosteronism, Ann NY Acad Sci, 970, 77, 10.1111/j.1749-6632.2002.tb04414.x Conn, 1965, Normokalemic Primary Aldosteronism. A Detectable Cause of Curable “Essential” Hypertension, JAMA, 193, 200, 10.1001/jama.1965.03090030022005 Mulatero, 2004, Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents, J Clin Endocrinol Metab, 89, 1045, 10.1210/jc.2003-031337 Fardella, 2006, Primary Hyperaldosteronism in the Hypertensive Disease, Curr Hypertens Reviews, 2, 36, 10.2174/157340206775473720 Mosso, 2003, Primary aldosteronism and hypertensive disease, Hypertension, 42, 161, 10.1161/01.HYP.0000079505.25750.11 Kaplan, 2001, Cautions over the current epidemic of primary aldosteronism, Lancet, 357, 953, 10.1016/S0140-6736(00)04223-9 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207 Milliez, 2005, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism, J Am Coll Cardiol, 45, 1243, 10.1016/j.jacc.2005.01.015 Fallo, 2006, Prevalence and characteristics of the metabolic syndrome in primary aldosteronism, J Clin Endocrinol Metab, 91, 454, 10.1210/jc.2005-1733 Lim, 2000, High prevalence of primary aldosteronism in the Tayside hypertension clinic population, J Hum Hypertens, 14, 311, 10.1038/sj.jhh.1001013 Montero, 1998, [Measurement of low levels of plasma renin activity. A methodological improvement], Rev Med Chil, 126, 151 Streeten, 1979, Reliability of screening methods for the diagnosis of primary aldosteronism, Am J Med, 67, 403, 10.1016/0002-9343(79)90786-1 Funder, 2008, Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline, J Clin Endocrinol Metab, 93, 3266, 10.1210/jc.2008-0104 Martinez-Aguayo, 2010, Aldosterone, plasma Renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population, Hypertension, 56, 391, 10.1161/HYPERTENSIONAHA.110.155135 Vallotton, 1996, Primary aldosteronism. Part I. Diagnosis of primary hyperaldosteronism, Clin Endocrinol (Oxf), 45, 47, 10.1111/j.1365-2265.1996.tb02059.x Arteaga, 2012 Connell, 1998, The adrenals, 1171 Reznek, 1994, The adrenal gland, Clin Endocrinol (Oxf), 40, 561, 10.1111/j.1365-2265.1994.tb03006.x Pascoe, 1992, Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2, Proc Natl Acad Sci U S A, 89, 8327, 10.1073/pnas.89.17.8327 Gordon, 1995, Primary aldosteronism, J Endocrinol Invest, 18, 495, 10.1007/BF03349761 Carvajal, 2011, A de novo unequal crossover mutation between CYP11B1 and CYP11B2 genes causes familial hyperaldosteronism type I, J Endocrinol Invest, 34, 140, 10.1007/BF03347044 MacConnachie, 1998, Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism, J Clin Endocrinol Metab, 83, 4328, 10.1210/jcem.83.12.5309 Mosso, 2001, Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives, Hypertension, 38, 688, 10.1161/01.HYP.38.3.688 Aglony, 2011, Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation, Hypertension, 57, 1117, 10.1161/HYPERTENSIONAHA.110.168740 Torpy, 1998, Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene, J Clin Endocrinol Metab, 83, 3214 Mulatero, 2011, Is familial hyperaldosteronism underdiagnosed in hypertensive children?, Hypertension, 57, 1053, 10.1161/HYPERTENSIONAHA.111.172916 Mulatero, 2008, A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III, J Clin Endocrinol Metab, 93, 2972, 10.1210/jc.2008-1241 Choi, 2011, K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension, Science, 331, 768, 10.1126/science.1198785 Scholl, 2012, Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5, Proc Natl Acad Sci U S A, 109, 2533, 10.1073/pnas.1121407109 Gagner, 1997, Laparoscopic adrenalectomy: lessons learned from 100 consecutive procedures, Ann Surg, 226, 238, 10.1097/00000658-199709000-00003 Shenker, 1989, Medical treatment of low-renin aldosteronism, Endocrinol Metab Clin North Am, 18, 415, 10.1016/S0889-8529(18)30377-3 Stowasser, 2000, Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension, J Clin Endocrinol Metab, 85, 3313, 10.1210/jcem.85.9.6834 Draper, 2005, 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action, J Endocrinol, 186, 251, 10.1677/joe.1.06019 Albiston, 1994, Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme, Mol Cell Endocrinol, 105, R11, 10.1016/0303-7207(94)90176-7 Ulick, 1979, A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol, J Clin Endocrinol Metab, 49, 757, 10.1210/jcem-49-5-757 Campino C, Carvajal CA, Cornejo J, et al. 11beta-hydroxysteroid dehydrogenase type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities in the pathogenia of essential hypertension. Endocrine 2009. Campino, 2013, Age-related changes in 11beta-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects, Am J Hypertens, 26, 481, 10.1093/ajh/hps080